A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19
Miyazaki T., Hosogaya N., Fukushige Y., Takemori S., Morimoto S., Yamamoto H., Hori M., Ozawa Y., Shiko Y., Inaba Y., Kurokawa T., Hanaoka H., Iwanami S., Kim K., Iwami S., Watashi K., Miyazawa K., Umeyama T., Yamagoe S., Miyazaki Y., Wakita T., Sumiyoshi M., Hirayama T., Izumikawa K., Yanagihara K., Mukae H., Kawasuji H., Yamamoto Y., Tarumoto N., Ishii H., Ohno H., Yatera K., Kakeya H., Kichikawa Y., Kato Y., Matsumoto T., Saito M., Yotsuyanagi H., Kohno S.
The anti-HIV drug nelfinavir suppresses the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro . However, its efficacy in patients with COVID-19 has not been studied.